Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.

被引：0
|
作者：
Schwartzberg, Lee S.
Bhat, Gajanan
Bharadwaj, Jayaram S.
Hlalah, Osama
Restrepo, Alvaro
Mehmi, Inderjit
Chawla, Shanta
Cobb, Patrick Wayne
机构：
[1] West Canc Ctr, Germantown, TN USA
[2] Spectrum Pharmaceut, Irvine, CA USA
[3] Pacific Canc Med Ctr, Anaheim, CA USA
[4] Bond Clin PA, Winter Haven, FL USA
[5] Texas Onc PA, Mcallen, TX USA
[6] City Hope Comprehens Canc Ctr, Simi Valley, CA USA
[7] Frontier Canc Ctr, Billings, MT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 31期
关键词：
D O I：
10.1200/JCO.2019.37.31_suppl.61
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
    Schwartzberg, Lee S.
    Bhat, Gajanan
    Bharadwaj, Jayaram S.
    Hlalah, Osama
    Restrepo, Alvaro
    Mehmi, Inderjit
    Chawla, Shanta
    Cobb, Patrick Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
    Moon, Yong Wha
    Kim, Seung Ki
    Lee, Keun Seok
    Lee, Moon Hee
    Park, Yeon Hee
    Park, Kyong Hwa
    Kim, Gun Min
    Lim, Seungtaek
    Lee, Seung Ah
    Choi, Jae Duk
    Baek, Eunhye
    Han, Hyesun
    Baek, Seungjae
    Im, Seock-Ah
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 766 - 777
  • [3] Eflapegrastim, a novel long-acting granulocyte-colony stimulating factor: Integrated safety results in patients with early-stage breast cancer treated with TC chemotherapy
    Schwartzberg, Lee S.
    Bhat, Gajanan
    Peguero, Julio
    Agajanian, Richy
    Bharadwaj, Jayaram
    Restrepo, Alvaro
    Hlalah, Osama
    Mehmi, Inderjit
    Chawla, Shanta
    Lebel, Francois
    Cobb, Patrick W.
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients.
    Xia, Wen
    Xu, Fei
    Yuan, Zhongyu
    Xu, Ruilian
    Jiang, Yi
    Wu, Zhiyong
    Lu, Qianyi
    Zheng, Qiufan
    Hong, Ruoxi
    Jiang, Kuikui
    Huang, Jiajia
    An, Xin
    Bi, XiWen
    Hong, Yun
    Pang, Danmei
    Zhang, Anqin
    Wang, Xianming
    Zhang, Qing
    Zhang, Haibo
    Wang, Shusen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Artificial intelligence methods to predict chemotherapy-induced neutropenia in breast cancer patients.
    DeWan, Peter Abdul
    Inbar, Orr
    Spina, Catherine S.
    Rudeen, Karl
    Lagor, Charles
    Walker, Mark S.
    Stepanski, Edward J.
    Nwankwo, Jennifer O.
    Hyde, Brigham
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Reflecting Change in Practice: Febrile Neutropenia Rates in Long-acting Compared with Short-acting GCSF Preparations in Breast Cancer Patients Undergoing Neoadjuvant and Adjuvant Chemotherapy
    Casswell, G.
    Gullick, G.
    Gibbs, L.
    Robinson, T.
    Jenner, A.
    Beresford, M. J.
    Bowen, R. L.
    CLINICAL ONCOLOGY, 2019, 31 (07) : E105 - E106
  • [7] A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
    Cobb, Patrick Wayne
    Moon, Yong Wha
    Mezei, Klara
    Lang, Istvan
    Bhat, Gajanan
    Chawla, Shanta
    Hasal, Steven J.
    Schwartzberg, Lee S.
    CANCER MEDICINE, 2020, 9 (17): : 6234 - 6243
  • [8] A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
    Zhang, Qingyuan
    Wang, Zhonghua
    Yao, Wei
    Wang, Shufang
    Zhang, Gaochong
    Chen, Jianmin
    Hou, Qingsong
    Li, Simon
    Li, Hongsheng
    Ye, Changsheng
    Sun, Tao
    Yang, Hongjian
    Chen, Zhendong
    Wang, Zhihong
    Liu, Xiaoan
    Geng, Cuizhi
    Li, Xingrui
    Zhang, Jin
    Zheng, Hong
    Shao, Zhimin
    BMC CANCER, 2024, 24 (01)
  • [9] Treatment patterns and outcomes in patients with breast cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia: Results from the MONITOR-GCSF study
    Aapro, M.
    Krendyukov, A.
    Krivtsova, N.
    Gascon, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S53 - S53
  • [10] Lipegfilgrastim highly cost-effective in reducing chemotherapy-induced neutropenia in breast cancer patients
    Akpo, E. I. H.
    Jansen, I. R.
    Maes, E.
    Simoens, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S44 - S44
12345